21Mar 2025
LYR-220 Improves CRS Symptoms Post-ESS With No Serious Events

LYR-220 Improves CRS Symptoms Post-ESS With No Serious Events

LYR-220 significantly improves CRS symptoms post-ESS. This Phase 2 BEACON study (42 patients) found no serious adverse events. At Week 24, LYR-220 improved SNOT-22 scores (−16.8, p=0.007), 3CS (−1.50, p=0.02), and ethmoid opacification (−8.14, p=0.035). Loss-of-smell improved from Week 8 (−0.87, p=0.026). Fewer LYR-220 patients required rescue steroids. Findings support LYR-220’s safety, efficacy, and long-acting benefit for CRS treatment.

  • #ent

Like

Save

Share